Dr. Kim on Combination Therapies in Lung Cancer

Edward S. Kim, MD
Published: Monday, Sep 12, 2016



Edward S. Kim, MD, chair, Solid Tumor Oncology and Investigational Therapeutics, Donald S. Kim Distinguished Chair for Cancer Research, Levine Cancer Institute, Carolinas HealthCare System, discusses combination therapies in the treatment of patients with lung cancer.

Kim expresses a genuine curiosity in observing how results will pan out over the next several years in multiple ongoing studies examining combination therapies in lung cancer. His only bias, he says, may lie in a preference for non-cytotoxic regimens.

Specifically, patients with epidermal growth factor receptor mutations have seen substantial benefits in their treatment regimens. Moreover, the very fact that patients with stage IV lung cancer can be administered an oral biologic therapy for several years represents significant progress in this space, says Kim.

He goes on to say that he hopes the field of immuno-oncology will see similar steps forward. It is important, he explains, to identify strategies that include lower side effects, that effectively control tumor growth, and that are generally more tolerable and less toxic for patients.


Edward S. Kim, MD, chair, Solid Tumor Oncology and Investigational Therapeutics, Donald S. Kim Distinguished Chair for Cancer Research, Levine Cancer Institute, Carolinas HealthCare System, discusses combination therapies in the treatment of patients with lung cancer.

Kim expresses a genuine curiosity in observing how results will pan out over the next several years in multiple ongoing studies examining combination therapies in lung cancer. His only bias, he says, may lie in a preference for non-cytotoxic regimens.

Specifically, patients with epidermal growth factor receptor mutations have seen substantial benefits in their treatment regimens. Moreover, the very fact that patients with stage IV lung cancer can be administered an oral biologic therapy for several years represents significant progress in this space, says Kim.

He goes on to say that he hopes the field of immuno-oncology will see similar steps forward. It is important, he explains, to identify strategies that include lower side effects, that effectively control tumor growth, and that are generally more tolerable and less toxic for patients.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Best Practice™: Choosing Therapies for Patients with EGFR-Mutant Lung Cancers: More Options... More Decisions... Better OutcomesFeb 28, 20182.0
Clinical Vignette Series: 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®Feb 28, 20182.0
Publication Bottom Border
Border Publication
x